Last reviewed · How we verify
Losartan (Control)
Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Losartan (Control) |
|---|---|
| Also known as | Cozar |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in blood pressure reduction and improved renal protection.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Heart failure with reduced ejection fraction
- Post-myocardial infarction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
Key clinical trials
- Losartan for Corneal Fibrosis (NA)
- Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19 (PHASE3)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) (PHASE2)
- A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) (PHASE3)
- Losartan and Social Processing (EARLY_PHASE1)
- Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) (PHASE2)
- Losartan and Emotional Processing in Young People (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losartan (Control) CI brief — competitive landscape report
- Losartan (Control) updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI